Suppr超能文献

转基因小鼠心脏中单体磷酸受纳蛋白的过表达。

Monomeric phospholamban overexpression in transgenic mouse hearts.

作者信息

Chu G, Dorn G W, Luo W, Harrer J M, Kadambi V J, Walsh R A, Kranias E G

机构信息

Department of Pharmacology & Cell Biophysics, University of Cincinnati (Ohio), College of Medicine 45267-0575, USA.

出版信息

Circ Res. 1997 Oct;81(4):485-92. doi: 10.1161/01.res.81.4.485.

Abstract

Phospholamban, a prominent modulator of the sarcoplasmic reticulum (SR) Ca(2+)-ATPase activity and basal contractility in the mammalian heart, has been proposed to form pentamers in native SR membranes. However, the monomeric form of phospholamban, which is associated with mutating Cys41 to Phe41, was shown to be as effective as pentameric phospholamban in inhibiting Ca2+ transport in expression systems. To determine whether this monomeric form of phospholamban is also functional in vivo, we generated transgenic mice with cardiac-specific overexpression of the mutant (Cys41-->Phe41) phospholamban. Quantitative immunoblotting indicated a 2-fold increase in the cardiac phospholamban protein levels compared with wild-type controls, with approximately equal to 50% of phospholamban migrating as monomers and approximately 50% as pentamers upon SDS-PAGE. The mutant-phospholamban transgenic hearts were analyzed in parallel with transgenic hearts overexpressing (2-fold) wild-type phospholamban, which migrated as pentamers upon SDS-PAGE. SR Ca(2+)-uptake assays revealed that the EC50 values for Ca2+ were as follows: 0.32 +/- 0.01 mumol/L in hearts overexpressing monomeric phospholamban, 0.49 +/- 0.05 mumol/L in hearts overexpressing wild-type phospholamban, and 0.26 +/- 0.01 mumol/L in wild-type control mouse hearts. Analysis of cardiomyocyte mechanics and Ca2+ kinetics indicated that the inhibitory effects of mutant-phospholamban overexpression (mt) were less pronounced than those of wild-type phospholamban overexpression (ov) as assessed by depression of the following: (1) shortening fraction (25% mt versus 45% ov), (2) rates of shortening (27% mt versus 48% ov), (3) rates of relengthening (25% mt versus 50% ov) (4) amplitude of the Ca2+ signal (21% mt versus 40% ov), and (5) time for decay of the Ca2+ signal (25% mt versus 106% ov) compared with control (100%) myocytes. The differences in basal cardiac, myocyte mechanics and Ca2+ transients among the animal groups overexpressing monomeric or wild-type phospholamban and wild-type control mice were abolished upon isoproterenol stimulation. These findings suggest that pentameric assembly of phospholamban is important for mediating its optimal regulatory effects on myocardial contractility in vivo.

摘要

受磷蛋白是哺乳动物心脏肌浆网(SR)Ca(2+)-ATP酶活性和基础收缩性的重要调节因子,有人提出它在天然SR膜中形成五聚体。然而,将半胱氨酸41突变为苯丙氨酸41所产生的受磷蛋白单体形式,在表达系统中抑制Ca2+转运方面与五聚体受磷蛋白效果相同。为了确定这种受磷蛋白单体形式在体内是否也有功能,我们构建了心脏特异性过表达突变型(半胱氨酸41→苯丙氨酸41)受磷蛋白的转基因小鼠。定量免疫印迹显示,与野生型对照相比,心脏受磷蛋白水平增加了2倍,在SDS-PAGE上约50%的受磷蛋白以单体形式迁移,约50%以五聚体形式迁移。将突变型受磷蛋白转基因心脏与过表达(2倍)野生型受磷蛋白的转基因心脏(在SDS-PAGE上以五聚体形式迁移)进行平行分析。SR Ca(2+)摄取试验显示,Ca2+的EC50值如下:过表达单体受磷蛋白的心脏中为0.32±0.01μmol/L,过表达野生型受磷蛋白的心脏中为0.49±0.05μmol/L,野生型对照小鼠心脏中为0.26±0.01μmol/L。心肌细胞力学和Ca2+动力学分析表明,与对照(100%)心肌细胞相比,过表达突变型受磷蛋白(mt)的抑制作用不如过表达野生型受磷蛋白(ov)明显,通过以下指标的降低来评估:(1)缩短分数(25% mt对45% ov),(2)缩短速率(27% mt对48% ov),(3)再伸长速率(25% mt对50% ov),(4)Ca2+信号幅度(21% mt对40% ov),(5)Ca2+信号衰减时间(25% mt对106% ov)。在异丙肾上腺素刺激后,过表达单体或野生型受磷蛋白的动物组与野生型对照小鼠之间基础心脏、心肌细胞力学和Ca2+瞬变的差异消失。这些发现表明,受磷蛋白的五聚体组装对于介导其在体内对心肌收缩性的最佳调节作用很重要。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验